Big pharma is constantly looking for new ways to control its multi-billion dollar budgets and speed up processes across R&D and commercial divisions. How tightly managers have been able to manage these targets has been a key internal metric. But what if one of these huge corporations were to abandon that core competency of controlling costs, and simply did away with budgets altogether?
Roche: We’ve Abandoned Budgets And It’s Liberated Employees
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?
More from Leadership
More from In Vivo
• By
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
• By
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
• By
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.